![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 19, 2021 12:03:31 PM
As you pointed out, the evidence against Remdesivir was plentiful and strong, yet it was ignored by our FDA. Other studies confirmed poor results and futility. In fact, data has shown that the mortality is actually higher among Remdesivir patients. Special allowances were made for its approval. Fauci claimed the emergency justified approval even though they were just trending towards positivity. Subgroups of data were used to reach that conclusion, but we ignored all of this because a pandemic was raging worldwide. Of course, exceptions had to be made during such a horrible emergency.
We assumed the FDA was just trying their best to find something, anything that they could call helpful, and then Leronlimab started showing spectacular results at Montefiore and UCLA through the EIND program. We expected immediate support and guidance from the FDA, and why not, Remdesivir got it for much less, and people were dying by the thousands every day. Safety was not an issue!! What did they have to lose? So we waited, holding our collective breath, thinking that of course the FDA would do something, that Fauci would talk about this drug showing so much promise. The one drug that was actually taking death off the table. But nothing, radio silence. Government and media blackout. Then we blamed the Trump administration, surely once they were removed we would start to see some progress? Nope, nada, zip.
Unlike others here, I don't blame Nader or Kelly or anyone at Cytodyn for being optimistic, for feeling sure that emergency use, recognition, some sort of acknowledgement was on the way. How could it not when the FDA had already set the bar so low with Remdesivir? How could Cytodyn not expect great things when people were literally getting up off their death beds within 14 days?!
At that time I was literally scouring the internet and the clinical trial sites, researching every possible drug in trials. I often wondered why given the emergency, an FDA taskforce was not assembled to review the data for every Covid trial in real time, to speed up assistance, and manufacturing for promising drugs. Imagine if Fauci and the NIH supported the Leronlimab trial effort with a larger trial or funding, imagine how many people could have been saved if they really wanted to help people. But it hasn't been about that in this country, it's about big pharma profits, and Fauci is complicit. What a shame he was carried over to the new administration.
So, needless to say, I'm very happy that Cytodyn has pivoted overseas, working to save lives where the need is greatest. The Israel Albert Einstein hospital in Brazil is a respected institution with much experience in clinical trials. Macleod's in India an extremely strong company with worldwide reach. This race has taken longer than I expected, the sprint turned into a marathon, but I have no doubt Leronlimab will get over the finish line.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 09:15:10 PM
- Form SC TO-I - Tender offer statement by Issuer • Edgar (US Regulatory) • 06/03/2024 09:10:56 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:17:30 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/06/2024 09:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 09:09:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/09/2024 02:30:20 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:16:47 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/01/2024 10:15:34 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/22/2024 10:16:11 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/22/2024 05:15:08 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/16/2024 02:00:24 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 10:31:57 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/29/2024 10:22:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/29/2024 01:40:14 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 10:15:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/16/2024 10:16:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:04:20 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2024 02:02:30 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM